Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Clinical trials sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New Dual-Target drug aims to beat current therapy for kidney Patients' hormone problem Results expected Nov 2026 (estimated)
-
New injection shows promise for dialysis patients with hormone imbalance
Disease control CompletedThis study tested a new drug called MT1013 in 115 adults with chronic kidney disease who are on dialysis and have a condition called secondary hyperparathyroidism (high parathyroid hormone). The goal was to see if the drug could safely lower hormone levels by at least 30%. Partic…
Phase 2 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug shows promise for dialysis patients with hormone disorder
Disease control CompletedThis study tested a new drug called MT1013 in 98 adults on kidney dialysis who have secondary hyperparathyroidism, a condition where parathyroid hormone levels are too high. The goal was to see if the drug is safe and can lower these hormone levels. Participants received either t…
Phase 2 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Tiny trial tracks new Drug's journey in dialysis patients
Knowledge-focused CompletedThis early-stage study looks at how the experimental drug MT1013 moves through and leaves the body of people on hemodialysis who have secondary hyperparathyroidism. Six participants will receive a single dose, and researchers will measure radioactivity in blood, urine, and stool …
Phase 1 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC